钠-葡萄糖协同转运蛋白2抑制剂在重症监护病房2型糖尿病患者中的应用:一项先导性病例对照研究
该先导性病例对照研究纳入18例接受恩格列净(10 mg每日一次)联合胰岛素、目标血糖范围10-14 mmol/l的ICU 2型糖尿病患者,按年龄、糖化血红蛋白A1c和ICU时长与72例未接受恩格列净但目标血糖范围相同的对照患者匹配。结果显示,治疗组与对照组最大钠升高中位数分别为9(3-12)mmol/l与3(1-10)mmol/l(P=0.045),氯升高分别为8(3-10)mmol/l与3(2-8)mmol/l(P=0.059),强离子差、pH或碱剩余无差异。两组低血糖发生率均为6%,治疗组无酮症酸中毒(对照组1例),肾功能恶化分别为18%与29%(P=0.54),尿培养阳性分别为22%与13%(P=0.28),院内死亡率分别为17%与19%(P=0.79)。作者认为,恩格列净治疗与钠、氯水平升高相关,但未显著关联酸解质改变、低血糖、酮症酸中毒、肾功能恶化、菌尿或死亡率。
要点
- 在ICU 2型糖尿病患者中,恩格列净(10 mg每日一次)联合胰岛素、目标血糖10-14 mmol/l,与最大钠升高中位数9(3-12)mmol/l相关,对照组为3(1-10)mmol/l(P=0.045)。
- 恩格列净组最大氯升高中位数8(3-10)mmol/l,对照组3(2-8)mmol/l(P=0.059),差异未达统计学显著。
- 两组强离子差、pH或碱剩余无差异;低血糖发生率均为6%;治疗组无酮症酸中毒,对照组1例。
- 肾功能恶化发生率治疗组18% vs 对照组29%(P=0.54),尿培养阳性22% vs 13%(P=0.28),院内死亡率17% vs 19%(P=0.79),均无显著差异。
适用人群与场景
- ICU 2型糖尿病患者,接受恩格列净10 mg每日一次联合胰岛素,目标血糖范围10-14 mmol/l(治疗组)。
- 对照组为ICU 2型糖尿病患者,未接受恩格列净,但暴露于相同目标血糖范围10-14 mmol/l,按年龄、糖化血红蛋白A1c和ICU时长与治疗组匹配。
处置流程与药物剂量
- 恩格列净10 mg每日一次,联合胰岛素,目标血糖范围10-14 mmol/l,依据本中心对糖尿病患者的宽松血糖控制方案(治疗组)。
研究设计与关键结果
- 先导性病例对照研究:纳入18例ICU 2型糖尿病患者为治疗组,72例为对照组,比较电解质和酸碱参数变化、低血糖、酮症酸中毒、肾功能恶化、尿培养结果和院内死亡率。
- 最大钠升高中位数:治疗组9(3-12)mmol/l vs 对照组3(1-10)mmol/l(P=0.045);最大氯升高中位数:治疗组8(3-10)mmol/l vs 对照组3(2-8)mmol/l(P=0.059)。
- 强离子差、pH或碱剩余无差异;低血糖发生率两组均为6%;酮症酸中毒治疗组0例,对照组1例。
- 肾功能恶化:治疗组18% vs 对照组29%(P=0.54);尿培养阳性:治疗组22% vs 对照组13%(P=0.28);院内死亡:治疗组17% vs 对照组19%(P=0.79)。
证据类型、等级与局限
- 证据类型:先导性病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在ICU 2型糖尿病患者中,恩格列净治疗与钠、氯水平升高相关,但未显著关联酸解质改变、低血糖、酮症酸中毒、肾功能恶化、菌尿或死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sodium glucose co-transporter-2 (SGLT2) inhibitors improve long-term cardiovascular and renal outcomes in individuals with type 2 diabetes. However, the safety of SGLT2 inhibitors in ICU patients with type 2 diabetes is uncertain. We aimed to perform a pilot study to assess the relationship between empagliflozin therapy and biochemical, and clinical outcomes in such patients.
METHODS: We included 18 ICU patients with type 2 diabetes receiving empagliflozin (10 mg daily) and insulin to target glucose range of 10-14 mmol/l according to our liberal glucose control protocol for patients with diabetes (treatment group). Treatment group patients were matched on age, glycated hemoglobin A1c, and ICU duration with 72 ICU patients with type 2 diabetes exposed to the same target glucose range but who did not receive empagliflozin (control group). We compared changes in electrolyte and acid-base parameters, hypoglycemia, ketoacidosis, worsening kidney function, urine culture findings, and hospital mortality between the groups.
RESULTS: Median (IQR) maximum increase in sodium and chloride levels were 3 (1-10) mmol/l and 3 (2-8) mmol/l in the control group and 9 (3-12) mmol/l and 8 (3-10) mmol/l in the treatment group (P = 0.045 for sodium, P = 0.059 for chloride). We observed no differences in strong ion difference, pH or base excess. Overall, 6% developed hypoglycemia in each group. No patient in the treatment group and one patient in the control group developed ketoacidosis. Worsening kidney function occurred in 18% and 29% of treatment and control group patients, respectively (P = 0.54). Urine cultures were positive in 22% of treatment group patients and 13% of control group patients (P = 0.28). Overall, 17% of treatment group patients and 19% of control group patients died in hospital (P = 0.79).
CONCLUSIONS: In our pilot study of ICU patients with type 2 diabetes, empagliflozin therapy was associated with increases in sodium and chloride levels but was not significantly associated with acid-base changes, hypoglycemia, ketoacidosis, worsening kidney function, bacteriuria, or mortality.
参考来源
- Mårtensson J, Cutuli SL, Osawa EA, et al. Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study. Crit Care. 2023. PMID: 37194077. doi:10.1186/s13054-023-04481-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。